Neurocrine Acquires Soleno, Launches First Treatment for Prader-Willi Syndrome
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 06 2026
0mins
Should l Buy NBIX?
Source: PRnewswire
- Acquisition Overview: Neurocrine is acquiring Soleno for $53 per share in cash, totaling $2.9 billion, reflecting a strong commitment to the rare disease market and expected to enhance Neurocrine's leadership in endocrinology.
- Market Performance of VYKAT XR: Since FDA approval in Q2 2025, VYKAT XR generated $190 million in revenue for 2025, with $92 million coming from Soleno in Q4 alone, indicating strong market adoption and potential for long-term revenue.
- Strategic Implications: This acquisition not only expands Neurocrine's portfolio of innovative medicines but also establishes a sustainable revenue growth platform, with VYKAT XR's intellectual property expected to extend into the mid-2040s, further solidifying the company's market position.
- Future Outlook: Neurocrine plans to leverage its robust commercial infrastructure to support the rollout of VYKAT XR, which is expected to improve care for Prader-Willi syndrome patients while creating long-term value for shareholders, demonstrating a deep commitment to patient needs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBIX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBIX
Wall Street analysts forecast NBIX stock price to rise
20 Analyst Rating
17 Buy
3 Hold
0 Sell
Strong Buy
Current: 133.250
Low
143.00
Averages
179.68
High
203.00
Current: 133.250
Low
143.00
Averages
179.68
High
203.00
About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Neurocrine's INGREZZA Shows Superior Treatment Persistence in Real-World Analysis
- Treatment Persistence Comparison: Neurocrine Biosciences' analysis reveals that 55.6% of patients on INGREZZA maintained therapy over six months, significantly higher than the 48.1% for AUSTEDO XR, indicating INGREZZA's clear advantage in treatment persistence, which may enhance patient quality of life.
- Switching Rates Difference: During the six-month follow-up, only 7.7% of INGREZZA patients switched therapies compared to 11.2% for AUSTEDO XR, suggesting that INGREZZA is more effective in minimizing medication switches, thereby reducing the treatment burden on patients.
- Median Discontinuation Time: The median time to discontinuation or switch for INGREZZA was over 180 days, while it was 129 days for AUSTEDO XR, highlighting INGREZZA's effectiveness in maintaining patient treatment and potentially lowering the risk of TD symptom recurrence.
- Clinical Data Support: The findings align with previous KINECT-PRO study results, where 57.8% of INGREZZA patients achieved symptomatic remission at 24 weeks, further reinforcing the significance of INGREZZA in treating tardive dyskinesia.
See More
INGREZZA Shows Superior Treatment Persistence in Tardive Dyskinesia
- Treatment Persistence Comparison: A retrospective analysis involving 2,988 patients revealed that 55.6% of those treated with INGREZZA maintained treatment after six months, significantly outperforming the 48.1% persistence rate of AUSTEDO XR, indicating INGREZZA's superior ability to sustain therapy and potentially enhance patient quality of life.
- Switching Rate Discrepancy: The study found that the switching rate for INGREZZA was 7.7%, compared to 11.2% for AUSTEDO XR, with this difference being statistically significant (p=0.0012), suggesting that INGREZZA effectively reduces treatment interruptions, thereby alleviating the disease burden on patients.
- Clinical Implications: The findings underscore the importance of sustained treatment, as INGREZZA's higher persistence may help mitigate the recurrence of movement disorder symptoms, thereby enhancing overall patient quality of life and supporting its position as a first-line therapy.
- Data Source and Methodology: The analysis utilized IQVIA's U.S. Longitudinal Access and Adjudication Data, employing propensity score matching to ensure balanced patient baseline characteristics, providing robust empirical evidence to inform clinical decision-making.
See More
INGREZZA Shows Superior Treatment Continuation Compared to AUSTEDO XR
- Treatment Continuation Comparison: In a real-world analysis of adults with tardive dyskinesia, patients on INGREZZA showed a treatment continuation rate of 55.6% over six months, significantly higher than AUSTEDO XR's 48.1%, indicating INGREZZA's stronger capability in maintaining treatment adherence, which may enhance patients' quality of life.
- Reduced Switching Rates: During the follow-up, only 7.7% of patients in the INGREZZA cohort switched to other therapies, compared to 11.2% in the AUSTEDO XR group, suggesting that INGREZZA is more effective in minimizing medication switches, thereby reducing the risk of treatment interruption.
- Extended Median Time to Discontinuation: The median time to discontinuation for the INGREZZA group exceeded 180 days, while it was 129 days for AUSTEDO XR, highlighting INGREZZA's potential to prolong treatment duration, which may provide patients with more stable therapeutic outcomes.
- Support for Clinical Decision-Making: This study provides crucial real-world evidence for clinical practice, emphasizing INGREZZA's potential as a first-line treatment, aiding physicians in making more informed decisions when treating tardive dyskinesia.
See More
NEUROCRINE BIOSCIENCES INC: OPPENHEIMER INCREASES TARGET PRICE TO $220, UP FROM $192
Company Overview: Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases.
Stock Price Update: The target price for Neurocrine Biosciences has been raised to $220 from a previous price of $192.
See More
Neurocrine Acquires Soleno for $2.9 Billion
- Transaction Value: Neurocrine's acquisition of Soleno for $53 per share totals $2.9 billion, adding the Vykat XR tablet to its portfolio, thereby enhancing its market position in treating Prader-Willi syndrome.
- Financing Conditions: The transaction is not subject to any financing conditions and is expected to close within 90 days, demonstrating Neurocrine's strong execution capabilities and market confidence in its acquisition strategy.
- Analyst Rating Upgrade: Oppenheimer raised Neurocrine's price target from $192 to $220 while maintaining an ‘Outperform’ rating, viewing the acquisition as a prime example of Neurocrine's industry-leading business development expertise.
- Market Sentiment: Retail sentiment around NBIX surged from ‘neutral’ to ‘extremely bullish’, while SLNO sentiment rose from ‘bullish’ to ‘extremely bullish’, indicating strong market optimism regarding the acquisition.
See More
Investigations into Multiple Medical Company Mergers
- Avanos Medical Acquisition: Avanos Medical is set to be acquired by American Industrial Partners for $25.00 per share in an all-cash deal valued at approximately $1.272 billion, with investigations focusing on whether the board breached fiduciary duties by failing to ensure a fair process for shareholders.
- Leggett & Platt Merger: Leggett & Platt will be acquired by Somnigroup International in an all-stock transaction valued at around $2.5 billion, where shareholders will receive 0.1455 shares of Somnigroup for each share of Leggett & Platt, raising concerns about potential fiduciary breaches by the board.
- Soleno Therapeutics Acquisition: Soleno is to be acquired by Neurocrine Biosciences for $53.00 per share in cash, representing a total equity value of approximately $2.9 billion, with investigations questioning the fairness of the deal given it is below the company's 52-week high of $90.32.
- Forian, Inc. Investigation: Forian will be acquired by an entity affiliated with CEO Max Wygod for $2.17 per share in cash, with investigations looking into whether the board failed to conduct a fair process, potentially impacting shareholder value.
See More
Neurocrine's INGREZZA Shows Superior Treatment Persistence in Real-World Analysis
- Treatment Persistence Comparison: Neurocrine Biosciences' analysis reveals that 55.6% of patients on INGREZZA maintained therapy over six months, significantly higher than the 48.1% for AUSTEDO XR, indicating INGREZZA's clear advantage in treatment persistence, which may enhance patient quality of life.
- Switching Rates Difference: During the six-month follow-up, only 7.7% of INGREZZA patients switched therapies compared to 11.2% for AUSTEDO XR, suggesting that INGREZZA is more effective in minimizing medication switches, thereby reducing the treatment burden on patients.
- Median Discontinuation Time: The median time to discontinuation or switch for INGREZZA was over 180 days, while it was 129 days for AUSTEDO XR, highlighting INGREZZA's effectiveness in maintaining patient treatment and potentially lowering the risk of TD symptom recurrence.
- Clinical Data Support: The findings align with previous KINECT-PRO study results, where 57.8% of INGREZZA patients achieved symptomatic remission at 24 weeks, further reinforcing the significance of INGREZZA in treating tardive dyskinesia.
See More
INGREZZA Shows Superior Treatment Persistence in Tardive Dyskinesia
- Treatment Persistence Comparison: A retrospective analysis involving 2,988 patients revealed that 55.6% of those treated with INGREZZA maintained treatment after six months, significantly outperforming the 48.1% persistence rate of AUSTEDO XR, indicating INGREZZA's superior ability to sustain therapy and potentially enhance patient quality of life.
- Switching Rate Discrepancy: The study found that the switching rate for INGREZZA was 7.7%, compared to 11.2% for AUSTEDO XR, with this difference being statistically significant (p=0.0012), suggesting that INGREZZA effectively reduces treatment interruptions, thereby alleviating the disease burden on patients.
- Clinical Implications: The findings underscore the importance of sustained treatment, as INGREZZA's higher persistence may help mitigate the recurrence of movement disorder symptoms, thereby enhancing overall patient quality of life and supporting its position as a first-line therapy.
- Data Source and Methodology: The analysis utilized IQVIA's U.S. Longitudinal Access and Adjudication Data, employing propensity score matching to ensure balanced patient baseline characteristics, providing robust empirical evidence to inform clinical decision-making.
See More
INGREZZA Shows Superior Treatment Continuation Compared to AUSTEDO XR
- Treatment Continuation Comparison: In a real-world analysis of adults with tardive dyskinesia, patients on INGREZZA showed a treatment continuation rate of 55.6% over six months, significantly higher than AUSTEDO XR's 48.1%, indicating INGREZZA's stronger capability in maintaining treatment adherence, which may enhance patients' quality of life.
- Reduced Switching Rates: During the follow-up, only 7.7% of patients in the INGREZZA cohort switched to other therapies, compared to 11.2% in the AUSTEDO XR group, suggesting that INGREZZA is more effective in minimizing medication switches, thereby reducing the risk of treatment interruption.
- Extended Median Time to Discontinuation: The median time to discontinuation for the INGREZZA group exceeded 180 days, while it was 129 days for AUSTEDO XR, highlighting INGREZZA's potential to prolong treatment duration, which may provide patients with more stable therapeutic outcomes.
- Support for Clinical Decision-Making: This study provides crucial real-world evidence for clinical practice, emphasizing INGREZZA's potential as a first-line treatment, aiding physicians in making more informed decisions when treating tardive dyskinesia.
See More
NEUROCRINE BIOSCIENCES INC: OPPENHEIMER INCREASES TARGET PRICE TO $220, UP FROM $192
Company Overview: Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases.
Stock Price Update: The target price for Neurocrine Biosciences has been raised to $220 from a previous price of $192.
See More
Neurocrine Acquires Soleno for $2.9 Billion
- Transaction Value: Neurocrine's acquisition of Soleno for $53 per share totals $2.9 billion, adding the Vykat XR tablet to its portfolio, thereby enhancing its market position in treating Prader-Willi syndrome.
- Financing Conditions: The transaction is not subject to any financing conditions and is expected to close within 90 days, demonstrating Neurocrine's strong execution capabilities and market confidence in its acquisition strategy.
- Analyst Rating Upgrade: Oppenheimer raised Neurocrine's price target from $192 to $220 while maintaining an ‘Outperform’ rating, viewing the acquisition as a prime example of Neurocrine's industry-leading business development expertise.
- Market Sentiment: Retail sentiment around NBIX surged from ‘neutral’ to ‘extremely bullish’, while SLNO sentiment rose from ‘bullish’ to ‘extremely bullish’, indicating strong market optimism regarding the acquisition.
See More
